THERAPY DOSSIER · th-0e4826f5eab1

Adeno-associated virus type 9 (AAV9)-mediated Serpina3n knockdown

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32900484 ↗2020Reported benefit

Serpina3n is closely associated with fibrotic procession and knockdown ameliorates bleomycin-induced pulmonary fibrosis.

MouseChemical/toxin

Model: Bleomycin-induced pulmonary fibrosis, with a parallel silica-induced model

Serpina3n was up-regulated in both silica and bleomycin models, peaking at week 3 and returning towards normal by week 10, and AAV-mediated knockdown in lung tissue alleviated bleomycin-induced fibrotic changes while disinhibiting chymotrypsin C.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…